Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd. 

Nurses, Talk AEs, Interstitial Lung Disease, Before Treating With T-DXd

Distant relapse-free survival was maintained with non-operative management of pMMR locally advanced rectal cancer. 

Non-Operative Management of Rectal Cancer Does Not Worsen Distant RFS

Belrestotug plus dostarlimab-gxly improved ORR in patients with previously untreated, unresectable, locally advanced or metastatic, PD-L1–high NSCLC. 

Belrestotug/Dostarlimab Improves Responses in PD-L1–High Lung Cancer

Patients with metastatic castration-resistant prostate cancer who received radium-223 prior to docetaxel had better quality of life and tolerability scores than those who received docetaxel first.

Giving Radium-223 Before Docetaxel Improves QOL in mCRPC

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Articles

The FDA approved neoadjuvant nivolumab plus chemo, followed by adjuvant nivolumab for non-small cell lung cancer without EGFR mutations or ALK rearrangements. 

FDA Approves Perioperative Nivolumab Regimen for NSCLC

Follow-up from the CARTITUDE-4 trial showed that cilta-cel improved survival over standard of care in pretreated myeloma. 

Cilta-Cel Continues to Boosts Survival in Pretreated Myeloma

Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Cilta-cel led to high response rates and a promising safety profile in a real-world population of patients with relapsed/refractory myeloma. 

Cilta-Cel Is Safe, Efficacious in Real-World Treatment of Myeloma

Belantamab mafodotin plus KRd had a a manageable safety profile and deep responses in pretreated multiple myeloma.

Belantamab Mafodotin, KRd Is Promising in Relapsed/Refractory Myeloma

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

Twitter

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

Authors

Cathy Belt, RN, MSN, AOCN, Abramson Cancer Center of the University of Pennsylvania, discusses possible steps individuals can take upon finding out they have an inherited cancer syndrome, such as mutations in the BRCA1 or BRCA2 genes.

Cathy Belt on How to Act on Inherited Cancer Symptoms

​Cathy Belt, RN, MSN, AOCN, Abramson Cancer Center of the University of Pennsylvania, discusses nurses’ role in detecting inherited cancer syndromes.

Cathy Belt on Detecting Inherited Cancer Syndromes

Management of Skin and Nail AEs: Advice to Patients and Caregivers

Video content above is prompted by the following:

What advice do you provide to patients and/or caregivers to manage their oral and skin toxicities?

Experts provide advice to patients and caregivers on managing oral and skin toxicities.

Early Symptom Detection and the Impact on Patient Outcomes in GVHD

Now, let's focus on the crucial role that the care team plays in identifying and managing symptoms for cGVHD patients, particularly those with advanced disease.

What are the key symptoms you look for when assessing cGVHD patients? How do you approach symptom identification, especially for those with advanced disease?

Can you explain the importance of early symptom identification and management in cGVHD? How does this affect patient outcomes?

Panelists discuss how the care team identifies and manages symptoms in chronic graft-versus-host disease patients, particularly those with advanced disease, emphasizing key symptoms to monitor, approaches to symptom identification, and the critical importance of early detection and management for improving patient outcomes.

Managing Severe Symptoms and Disease Progression in the GVHD Journey

Can you describe the typical disease course for cGVHD patients, particularly those who progress to third-line treatment and beyond? What are some of the most severe symptoms they face?

How does the burden of cGVHD impact a patient's quality of life, and what are some of the long-term consequences if symptoms are not properly managed?

Panelists discuss how chronic graft-versus-host disease typically progresses in patients requiring third-line treatment and beyond, focusing on severe symptoms, the impact on quality of life, and potential long-term consequences of inadequately managed symptoms.

Comprehensive Patient Education and Symptom Awareness with GVHD

As an NP, how do you approach educating patients about cGVHD and its potential long-term effects? What resources or educational materials have you found most helpful in supporting patients and their caregivers? (brochures, apps, websites, videos?)

Panelists discuss how nurse practitioners educate patients about chronic graft-versus-host disease (cGVHD) and its long-term effects, exploring various educational resources and materials such as brochures, apps, websites, and videos that are most effective in supporting patients and their caregivers.

Chronic Graft-versus-Host Disease: Understanding the Disease and Its Widespread Symptoms

Can you provide some background on cGVHD? How does it differ from acute GVHD, and what are the main challenges it presents for patients?

From your experience, what are the most common symptoms you see in cGVHD patients, and how do these symptoms impact their daily lives?

Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.

Prophylactic Strategies and Advice for Managing AEs in  Bispecific Therapies 

What are some prophylactic measures taken to manage potential adverse events associated with talquetamab and other bispecifics?

What advice do you have for other health care providers who are involved in or about to be involved in the care of patients on talquetamab?

Experts discuss prophylactic measures for managing potential adverse events associated with talquetamab and other bispecifics, while all faculty will offer advice for health care providers involved in the care of patients receiving talquetamab.

Cathy Belt, RN, MSN, AOCN

Articles

Latest Updated Articles

Latest Conference Coverage